Neura Therapeutik

Neura Therapeutik is a private U.S. pain specialty company focused on developing and commercializing innovative analgesics, with an emphasis on abuse-deterrent, long-acting opioid products. The company was founded in 2010 by executives with prior experience in analgesic commercialization and has described business units for in-licensing and commercial consulting alongside internal product development. Publicly disclosed pipeline information is limited, but Neura has identified lead candidates NL-001 and NL-002 as proprietary abuse-deterrent versions of marketed long-acting opioids. Its value proposition appears to center on formulation technologies designed to resist crushing, extraction, and alcohol co-ingestion while maintaining extended-release properties. In addition to internal programs, the company has offered commercialization, regulatory, CMC, manufacturing scale-up, and launch support in the analgesics market.